Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology.
Humans
Female
Pregnancy
Inflammasomes
/ metabolism
NLR Family, Pyrin Domain-Containing 3 Protein
/ metabolism
Adult
Placenta Diseases
/ pathology
Interleukin 1 Receptor Antagonist Protein
/ therapeutic use
Interleukin-1beta
/ metabolism
Placenta
/ metabolism
CARD Signaling Adaptor Proteins
/ genetics
Pregnancy Outcome
Recurrence
Infant, Newborn
Chorionic Villi
/ metabolism
Chronic Disease
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
15
03
2024
accepted:
14
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Chronic histiocytic intervillositis of unknown origin (CHI) is a rare placental disorder associated with adverse pregnancy outcomes, frequent recurrence, and a lack of effective preventive strategies. Recent insights indicate a potential link between CHI-associated inflammatory lesions and the inflammasome pathway, suggesting innovative therapeutic avenues. Here we show a potential role of the inflammasome pathway in CHI through comprehensive transcriptomic analysis of grade 2 or 3 histopathologic CHI samples, paired with placental controls. Additionally, we present case studies of three individuals with recurrent CHI, who have undergone treatment with anakinra and colchicine throughout pregnancy, resulting in improved perinatal outcomes. Notably, all cases are characterized by the birth of healthy, full-term infants, with reduced or absent intervillositis recurrence. Placental assessment unveils heightened activation of the NLRP3-PYCARD inflammasome pathway and IL-1β processing in CHI samples, with downregulation observed in treated pregnancy samples, devoid of intervillositis. Collectively, these findings suggest a potential therapeutic role for targeting the inflammasome pathway in preventing recurrent CHI in pregnant individuals.
Identifiants
pubmed: 39477918
doi: 10.1038/s41467-024-53591-w
pii: 10.1038/s41467-024-53591-w
doi:
Substances chimiques
Inflammasomes
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Interleukin 1 Receptor Antagonist Protein
0
Interleukin-1beta
0
NLRP3 protein, human
0
CARD Signaling Adaptor Proteins
0
PYCARD protein, human
0
Types de publication
Journal Article
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
9396Informations de copyright
© 2024. The Author(s).
Références
Labarrere, C. & Mullen, E. Fibrinoid and trophoblastic necrosis with massive chronic intervillositis: an extreme variant of villitis of unknown etiology. Am. J. Reprod. Immunol. Microbiol 15, 85–91 (1987).
doi: 10.1111/j.1600-0897.1987.tb00162.x
pubmed: 3434661
Jacques, S. M. & Qureshi, F. Chronic intervillositis of the placenta. Arch. Pathol. Lab Med 117, 1032–1035 (1993).
pubmed: 8215826
Parant, O., Capdet, J., Kessler, S., Aziza, J. & Berrebi, A. Chronic intervillositis of unknown etiology (CIUE): Relation between placental lesions and perinatal outcome. Eur. J. Obstet. Gynecol. Reprod. Biol. 143, 9–13 (2009).
doi: 10.1016/j.ejogrb.2008.06.012
pubmed: 19121887
Marchaudon, V. et al. Chronic histiocytic intervillositis of unknown etiology: Clinical features in a consecutive series of 69 cases. Placenta 32, 140–145 (2011).
doi: 10.1016/j.placenta.2010.11.021
pubmed: 21183219
Mekinian, A. et al. Chronic histiocytic intervillositis: Outcome, associated diseases and treatment in a multicenter prospective study. Autoimmunity 48, 40–45 (2015).
doi: 10.3109/08916934.2014.939267
pubmed: 25028066
Mattuizzi, A. et al. Adverse perinatal outcomes of chronic intervillositis of unknown etiology: an observational retrospective study of 122 cases. Sci. Rep. 10, 12611 (2020).
doi: 10.1038/s41598-020-69191-9
pubmed: 32724097
pmcid: 7387519
Homatter, C. et al. Is chronic histiocytic intervillositis a severe placental disease? A case-control study. Placenta 91, 31–36 (2020).
doi: 10.1016/j.placenta.2019.12.020
pubmed: 32174304
Simula, N. K. et al. Chronic Intervillositis of Unknown Etiology (CIUE): Prevalence, patterns and reproductive outcomes at a tertiary referral institution. Placenta 100, 60–65 (2020).
doi: 10.1016/j.placenta.2020.07.032
pubmed: 32841927
Brady, C. A. et al. Immunomodulatory therapy reduces the severity of placental lesions in chronic histiocytic Intervillositis. Front Med 8, 753220 (2021).
doi: 10.3389/fmed.2021.753220
Brady, C. A. et al. Chronic histiocytic intervillositis: A breakdown in immune tolerance comparable to allograft rejection? Am. J. Reprod. Immunol. 85, e13373 (2021).
doi: 10.1111/aji.13373
pubmed: 33155353
Benachi, A. et al. Chronic histiocytic intervillositis: manifestation of placental alloantibody-mediated rejection. Am. J. Obstet. Gynecol. 225, 662.e1–662.e11 (2021).
doi: 10.1016/j.ajog.2021.06.051
pubmed: 34126086
Nedberg, N. H. et al. Platelet alloimmunization is associated with low grade chronic histiocytic intervillositis - A new link to a rare placental lesion? Placenta 112, 89–96 (2021).
doi: 10.1016/j.placenta.2021.07.291
pubmed: 34329972
C.Weel, I. et al. Increased expression of NLRP3 inflammasome in placentas from pregnant women with severe preeclampsia. J. Reprod. Immunol. 123, 40–47 (2017).
doi: 10.1016/j.jri.2017.09.002
pubmed: 28915449
Kohli, S. et al. Maternal extracellular vesicles and platelets promote preeclampsia via inflammasome activation in trophoblasts. Blood 128, 2153–2164 (2016).
doi: 10.1182/blood-2016-03-705434
pubmed: 27589872
Stødle, G. S. et al. Placental inflammation in pre-eclampsia by Nod-like receptor protein (NLRP)3 inflammasome activation in trophoblasts. Clin. Exp. Immunol. 193, 84–94 (2018).
doi: 10.1111/cei.13130
pubmed: 29683202
pmcid: 6038006
Megli, C., Morosky, S., Rajasundaram, D. & Coyne, C. B. Inflammasome signaling in human placental trophoblasts regulates immune defense against Listeria monocytogenes infection. J. Exp. Med. 218, e20200649 (2021).
doi: 10.1084/jem.20200649
pubmed: 32976558
Silvis, M. J. M. et al. Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy. Atherosclerosis 334, 93–100 (2021).
doi: 10.1016/j.atherosclerosis.2021.08.005
pubmed: 34492522
Leung, Y. Y., Yao Hui, L. L. & Kraus, V. B. Colchicine—Update on mechanisms of action and therapeutic uses. Semin. Arthritis Rheumat. 45, 341–350 (2015).
doi: 10.1016/j.semarthrit.2015.06.013
Fenton, T. R. & Kim, J. H. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 13, 59 (2013).
doi: 10.1186/1471-2431-13-59
pubmed: 23601190
pmcid: 3637477
Contro, E., deSouza, R. & Bhide, A. Chronic intervillositis of the placenta: A systematic review. Placenta 31, 1106–1110 (2010).
doi: 10.1016/j.placenta.2010.10.005
pubmed: 21035849
Brien, M.-E. et al. A systematic review of the safety of blocking the IL-1 system in human pregnancy. JCM 11, 225 (2021).
doi: 10.3390/jcm11010225
pubmed: 35011965
pmcid: 8745599
Indraratna, P. L. et al. Use of colchicine in pregnancy: a systematic review and meta-analysis. Rheumatology 57, 382–387 (2018).
doi: 10.1093/rheumatology/kex353
pubmed: 29029311
Duley L., Henderson-Smart D. J., Meher S. & King J. F. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007;CD004659
Russell, M. D. et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology 62, e48–e88 (2022).
doi: 10.1093/rheumatology/keac551
pmcid: 10070073
Askie L. M., Duley L., Henderson-Smart D. J. & Stewart L. A. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 369, 1791–1798 (2007).
Bouariu, A. et al. The potential benefit of hydroxychloroquine in chronic placental inflammation of unknown etiology associated with adverse pregnancy outcomes. Healthcare 10, 168 (2022).
doi: 10.3390/healthcare10010168
pubmed: 35052331
pmcid: 8775717
Danaher, P. et al. Gene expression markers of Tumor Infiltrating Leukocytes. J. Immunother. Cancer 5, 18 (2017).
doi: 10.1186/s40425-017-0215-8
pubmed: 28239471
pmcid: 5319024
Urrutia, A. et al. Standardized whole-blood transcriptional profiling enables the deconvolution of complex induced immune responses. Cell Rep. 16, 2777–2791 (2016).
doi: 10.1016/j.celrep.2016.08.011
pubmed: 27568558
Dray S. & Dufour A.-B. The ade4 Package: Implementing the duality diagram for ecologists. J Stat Soft 2007;22. Available from: http://www.jstatsoft.org/v22/i04/